Systemic thrombolytic therapy of acute ischemic stroke with rtPA

References

• Taylor TN, Davis PH, Tomer JC, Holmes J, Meyer JW, Jacobson MF. Lifetime costs of stroke in the United States. Stroke 27, 1459–1466 (1996).
   PubMed Web of Science ®Google Scholar
• Adams HP, Brott TG, Furlan AJ et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Stroke 27, 1711–1718 (1996).
   PubMed Web of Science ®Google Scholar
• ••Although more than 5 years old, these guidelines, which are mainly derived from the NINDS trial, are still a valid basis for everyone performing iv. thrombolysis.
   Google Scholar
• Quality Standards Subcommittee of the American Academy of Neurology. Practice Advisory: Thrombolytic therapy for acute ischemic stroke - summary statement. Neurology 47, 835–839 (1996).
   PubMed Web of Science ®Google Scholar
• Kaste M, Thomassen L, Grond M et al Thrombolysis for acute ischemic stroke. A consensus statement of the 3rd Karolinska Stroke Update, October 30–31,2000. Stroke32, 2717–2718 (2001).
   Google Scholar
• Fagan SC, Morgenstern LB, Petitta A et al. and the NINDS rt-PA Stroke Study Group. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology50, 883–890 (1998).
   Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl. J. Merl 333, 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• ••The pivotal trial for iv. thrombolysis withrtPA; logistically unsurpassed and (perhaps) unreproducable. Based on the results of this trial, rtPA was approved for ischemic stroke.
   Google Scholar
• Katzan IL, Sila CA, Furlan AJ. Community use of iv. tissue plasminogen activator for acute stroke. Results of the brain matters stroke management survey. Stoke 32,861–865 (2001).
   Google Scholar
• Hacke W, Brott T, Caplan L et al Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology53(7 Suppl. 4), S3—S14 (1999).
   Google Scholar
• Marler JR, Tilley BC, Lu M, Brott TG et al., for the NINDS rt-PA Stroke Study Group. Early stroke treatment associated with better outcome. The NINDS rt-PA Stroke Study. Ailoology55, 1649–1655 (2000).
   Google Scholar
• Alberts MJ, Hademenos G, Latchaw RE et al for the Brain Attack Coalition. Recommendations for the establishment of primary stroke centers. JAIVIA 283,3102–3109 (2000).
   Google Scholar
• Kwiatkowski TG, Libman RB, Frankel M et al for the NINDS Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl. j Merl 340,1781–1787 (1999).
   Google Scholar
• Patel SC, Levine SR, Tilley BC et al, for the NINDS Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JA/V/A 286,2830–2838 (2001).
   Google Scholar
• Hacke W Kaste M, Fieschi C et al, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Co-operative Acute Stroke Study (ECASS). JA/V/4 274,1017–1025 (1995) .
   Google Scholar
• ••Actually the first published large-scale randomized controlled trial of rtPA for ischemic stroke. Provides important contributions to define the limitations (practically and with regard to rtPA dose) of iv. thrombolysis with rtPA.
   Google Scholar
• Hacke W, Kaste M, Fieschi C et al for the 2nd European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with iv. alteplase in acute ischaemic stroke. Lancet352,1245–1251 (1998).
   Google Scholar
• •To date, the largest randomized controlled trial. For the first time, a favorable outcome is defined in terms of independence, probably a more realistic approach.
   Google Scholar
• Clark WM, Wissman S, Albers GW et al for the ATLANTIS Study Investigators. Recombinant tissue-type plasmonigen activator (alteplase) for ischemic stroke 3 to 5 h after symptom onset. The ATLANTIS study: a randomized controlled trial. JAIVIA 282,2019-2026 (1999).
   Google Scholar
• Albers GW, Clark WM, Madden IQ, Hamilton SA. ATLANTIS trial. Results for patients treated within 3 h of stroke onset. Stroke 33,493–497 (2002).
   Google Scholar
• Zweifler RM, Brody ML, Graves GC et al, Intravenous t-PA for acute ischemic stroke: therapeutic yield of a stroke code system. Neurology50, 501–503 (1998).
   PubMed Web of Science ®Google Scholar
• Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC for the OSF Stroke Team. Treating acute stroke patients with iv. tPA. The OSF Stroke Network Experience. Stroke 31,77–81 (2000).
   Google Scholar
• Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JA/V/A 283,1145–1150 (2000).
   Google Scholar
• •Largest Phase IV study published to date. The results indicate that systemic thrombolysis with rtPA can be performed safely and effectively in daily routine.
   Google Scholar
• Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland area experience. JAIVIA 283,1151–1158 (2000).
   Google Scholar
• •This study dampened the growing enthusiasm about thrombolysis, but nevertheless provides much needed cautions with respect to extending thrombolytic therapy to routine clinical practice.
   Google Scholar
• Mohr JR Thrombolyfic therapy for ischemic stroke. From clinical trials toclinical practice (editorial). JAIVIA 283, 1189–1190 (2000).
   PubMed Web of Science ®Google Scholar
• Tanne D, Bates VE, Verro P et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology 53, 424–427 (1999).
   PubMed Web of Science ®Google Scholar
• Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurru C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 32,12–16 (2001).
   Google Scholar
• Akins PT, Delemos C, Wentworth D, Byer J, Schorer SJ, Atkinson RP. Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke? Neurology 55, 1801–1805 (2000).
   PubMed Web of Science ®Google Scholar
• •Suggests that neurological and netu-oradiological advice and supervision enables non-neurologists to perform iv. thrombolysis safely and effectively.
   Google Scholar
• Johnston SC, Fung LH, Gillum LA et al. Utilization of iv. tissue-type plasminogen activator for ischemic stroke at academical medical centers: the influence of ethnicity. Shoke 32,1061–1068 (2001).
   Google Scholar
• Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and in-patient mortality rates for patients with ischemic stroke treated in community hospitals. Shoke 32,1832–1840 (2001).
   Google Scholar
• Grotta JC, Burgin WS, El-Mitwalli A et al Intravenous tissue-type plasminogen activator therapy for ischemic stroke. Houston experience 1996 to 2000. Awl?. Neuml. 58,2009-2013 (2001).
   Google Scholar
• Merino JG, Silver B, Wong E et al for the Ontario Stroke Program. Extending tissue plasminogen activator use to community and rural stroke patients. Stroke 33,141–146 (2002).
   Google Scholar
• Grond M, Stenzel C, Schmuelling S et al Early iv. thrombolysis for acute ischemic stroke in a community-based approach. Shoke 29,1544–1549 (1998).
   Google Scholar
• •Emphasizes that modifications of the emergency system can markedly increase the proportion of thrombolyses among stroke patients.
   Google Scholar
• Chapman KM, Woolfenden AR, Graeb D et al Intravenous tissue plasminogen www.future-drugs.com activator for acute ischemic stroke. A Canadian hospital experience. Stroke 31, 2920–2924 (2000).
   Google Scholar
• Buchan AM, Barber PA, Newcommon N et al Effectiveness oft-PA in acute ischemic stroke. Outcome relates to appropriateness. Neurology54, 679–684 (2000).
   PubMed Web of Science ®Google Scholar
• Koennecke H-C, Nohr R, Leistner S, Marx P Intravenous tPA for ischemic stroke. Team performance over time, safety and efficacy in a single-center, 2-year experience. Stroke 32, 1074–1078 (2001).
   Google Scholar
• •Demonstrates the learning-by-doing' effect with respect to in-hospital logistics in the management of hyperacute stroke.
   Google Scholar
• Trouillas P, Nighoghossian N, Derex L et al Thrombolysis with iv. rtPA in a series of 100 cases of acute carotid territory stroke. Determination of etiological, topographic and radiological outcome factors. Stroke 29, 2529–2540 (1998).
   Google Scholar
• Demchuk AM, Tanne D, Hill MD et al and the Multicentre tPA Stroke Survey Group. Predictors of good outcome after iv. tPA for acute ischemic stroke. Neumlogy57, 474–480 (2001).
   Google Scholar
• The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after iv. t-PAtherapy for ischemic stroke. Stroke 28, 2109–2118 (1997).
   PubMed Web of Science ®Google Scholar
• Demchuk AM, Morgenstern LB, Krieger DW et al Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stmke 30,34–39 (1999).
   Google Scholar
• von Kummer R, Allen KL, Holle R et al Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology205, 327–333 (1997).
   PubMed Web of Science ®Google Scholar
• •Emphasizes the usefulness and potential of CT in the evaluation of patients for thrombolytic treatment based on the experiences from the ECASS I trial.
   Google Scholar
• Levy DE, Brott TG, Haley EC et al Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stmke 25,291–297 (1994).
   Google Scholar
• Brott T, Lu M, Kothari R et al, for the NINDS rt-PA Stroke Study Group. Hypertension and its treatment in the NINDS rt-PA stroke trial. Stroke 29,1504–1509 (1998).
   Google Scholar
• Larrue V, von Kummer R, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australasian Acute Stroke Study (ECASSStmke 32,438–441 (2001).
   Google Scholar
• Grotta JC, Welch KMA, Fagan SC et al and the NINDS rt-PA Stroke Study Group. Clinical deterioration following improvement in the NINDS rt-PA stroke trial. Stroke 32,661–668 (2001).
   Google Scholar
• Schlaug G, Benfield A, Baird AE et al The ischemic penumbra. Operationally defined by diffusion and perfusion MRI. Neumlogy 53,1528–1537 (2000).
   Google Scholar
• Kidwell CS, Saver JL, Mattiello J et al Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neuro147, 462–469 (2000).
   Google Scholar
• •The effect of thrombolytic treatnent is persuasively demonstrated by modem brain imaging techniques.
   Google Scholar
• Schellinger PD, Jansen 0, Fiebach JB et al Monitoring iv. recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stmke 31,1318–1328 (2000).
   Google Scholar
• •Illustrative examples of possible criteria to identify ideal and non-ideal candidates for thrombolysis by means of 'stroke MRI'.
   Google Scholar
• Parsons MW, Barber PA, Chalk J et al Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann. Neural 51,28–37 (2002).
   PubMed Web of Science ®Google Scholar
• •See [43].
   Google Scholar
• Heiss W-D, Kracht LW Thiel A, Grond M, Pawlik G. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischemia. Brain 124,20–29 (2001).
   Google Scholar
• von Kummer R, Weber J. Brain and vascular imaging in acute ischemic stroke. The potential of computed tomography. Neurology 49\(Suppl. 4), S52—S55 (1997).
   Google Scholar
• von Kummer R, Bourquain H, Bastianello S et al for the ECASS II Group. Early prediction of irreversible brain damage after ischemic stroke at CT Radiology219,95–100 (2001).
   Google Scholar
• Grotta JC, Chiu D, Lu M et al and the NINDS rt-PA Stroke Trial Study Group. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for iv. rtPA therapy. Stroke 30,1528–1533 (1999).
   Google Scholar
• Kalafut MA, Schriger DL, Saver JL, Starkman S. Detection of early CT signs of >1/3 middle cerebral artery infarctions: interrater reliability and sensitivity of CT interpretation by physicians involved in acute stroke care. Stmke 31,1667–1671 (2000).
   Google Scholar
• von Kummer R. Effect of training in reading CT scans on patient selection for ECASS II.Neumlogy51(2 Suppl. 3), S50—S52 (1998).
   Google Scholar
• Wardlaw JM, Dorman PJ, Lewis SC, Sandercock PAG. Can stroke physicians and neurologists identify signs of early cerebral infarction on CT? I Neural Neurosurg. Psychiatry67, 651–653 (1999).
   Google Scholar
• Barber PA, Demchuk AM, Zhang J, Buchan AM, for the ASPECTS Study Group. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet355, 1670–1674 (2000).
   Google Scholar
• •This study validates an interesting new grading system for early ischemic changes on CT, which might help to reduce inter-rater variabilities in CT interpretation.
   Google Scholar
• Pexrnan JHW, Barber PA, Hill MD et al Use of the Alberta Stroke Program early CT score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am Neuroradial 22,1534–1542 (2001).
   PubMed Web of Science ®Google Scholar
• Caplan LR, Mohr JP, Kistler JP, Koroshetz W Thrombolysis - not a panacea forischemic stroke. N Engl. I Med. 337, 1309–1310 (1997).
   PubMed Web of Science ®Google Scholar
• •Interesting debate regarding thrombolysis for ischemic stroke. A more conservative attitude is confronted with pragmatism and a more optimistic approach.
   Google Scholar
• Grotta JC. t-PA - the best current option for most patients. N Engl. I Med. 337, 1310–1313 (1997).
   PubMed Web of Science ®Google Scholar
• •See [55].
   Google Scholar
• Lewandowski CA, Frankel M, Tomsick TA et al. Combined iv. and intra-arterial r-TPA Vel3U5 intra-arterial therapy of acute ischemic stroke. Emergency management of stroke (EMS) bridging trial. 9mke30, 2598–2605 (1999).
   Google Scholar
• Ernst R, Pancioli A, Tomsick T et al Combined iv. and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 31,2552–2557 (2000).
   Google Scholar
• Ringelstein EB, Biniek R, Weiner C, Ammeling B, Nolte PN, Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology42, 289–298 (1992).
   PubMed Web of Science ®Google Scholar
• Alexandrov AV, Demchuk AM, Felberg RA et al High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial Doppler monitoring. Stroke 31, 610–614 (2000).
   PubMed Web of Science ®Google Scholar
• Furlan A, Higashida R, Wechsler L et al, for the PROACT Investigators. Intra-arterial prourokinase for acute ischemic sinike. The PROACT II study: a randornized controlled trial. JA/V/A 282, 2003-2011 (1999).
   Google Scholar
• •First large-scale, randomized controlled trial testing the use of intra-arterial thrombolysis. On one hand, this study proved the efficacy of the intra-arterial concept, on the other hand the question of whether this concept is feasible in daily stroke care is raised.
   Google Scholar
• Hacke W, Zeumer H, Ferbert A, Brückmann H, del Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 19, 1216–1222 (1988).
   Google Scholar
• Brandt T, von Kummer R, Muller-KOppers M, Hacke W Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke27, 875–881 (1996).
   Google Scholar
• Levine SR, Gorman M. `Telestroke'. The application of telemedicine for stroke. Stroke 30, 464–469 (1999).
   PubMed Web of Science ®Google Scholar
• Kothari R, Sauerbeck L, Jauch E et al Patient's awareness of stroke signs, symptoms and risk factors. Stroke 28, 1871–1875 (1997).
   PubMed Web of Science ®Google Scholar
• Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56, 1015–1020 (2001).
   Google Scholar
• •Helpful analysis of the shortcomings in the treatment of hyperacute ischemic stroke.
   Google Scholar
• Merino JG, Silver B, Wong E, Demaerschalk B, Tamayo A, Hachinski V. Physician Knowledge of the Benefits, Risks and Contraindications of Tissue Plasminogen Activator for Acute Ischemic Stroke. Stroke 32, 2208–2209 (2001).
   PubMed Web of Science ®Google Scholar
• Menon SC, Pandey DK, Morgenstern LB. Critical factors determining access to acute stroke care. Neurology51, 427–432 (1998).
   Google Scholar
• Salisbury HR, Banks BJ, Footitt DR, Winner SJ, Reynolds DJ. Delay in presentation of patients with acute stroke to hospital in Oxford. QJNI91, 635–640 (1998).
   Google Scholar
• Johnston F, Wardlaw J, Dennis MS et al Delays in stroke referrals. Lancet 354, 47–48(1999).
   PubMed Web of Science ®Google Scholar
• Wester P, Radberg J, Lundgren B, Peltonen M for the Seek-Medical-Attention-in-Time Study Group. Factors associated with delayed admission to hospital and in-hospital delays in acute stroke and TIA. A prospective, multicenter study. Stroke 30, 40–48 (1999).
   Google Scholar
• Bratina P, Greenberg L, Pasteur W, Grotta JC. Current emergency department management of stroke in Houston, Texas. Stroke 26, 409–414 (1995).
   PubMed Web of Science ®Google Scholar
• Rapp K, Bratina P, Barch C et al Code stroke: rapid transport, triage and treatment using rt-PA therapy. The NINDS rt-PA Stroke Study Group. J. Neurosci. NUTS. 29, 361–366 (1997).
   Google Scholar
• Spengos K, Behrens S, Daffertshofer M, Dempfle CE, Hennerici M. Acceleration of thrombolysis with ultrasound through the cranium in a flow model. Ultrasouncl Merl Biol. 26, 889–895 (2000).
   Google Scholar
• Davydov L, Cheng JW. Tenecteplase: a review. Clin. Ther. 23, 982–997 (2001).
   PubMed Web of Science ®Google Scholar
• Gibson CM, Marble SJ. Issues in the assessment of the saferty and efficacy of tenecteplase (TNK-tPA). Gun. Cardiol 24, 577–584 (2001).
   Web of Science ®Google Scholar
• Chapman DF, Lyden P, Lapchak PA et al Comparison of TNK with wild type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 32, 748–752 (2001).
   PubMed Web of Science ®Google Scholar
• Kaste M. Thrombolysis in ischaemic stroke-present and future: role of combined therapy. Cerebrovasc. Dis. 11 (Suppl. 1), 55–59 (2001).
   Google Scholar
• Devuyst G, Bogousslavsky J. Update on recent progress in drug treatment for acute ischemic stroke. j Neural 248, 735–742 (2001).
   PubMed Web of Science ®Google Scholar
• Yang Y, Li Q, Miyashita H, Howlett W, Siddiqui M, Shuaib A. Usefulness of postischemic thrombolysis with or without neuroprotection in a focal embolic model of cerebral ischemia. j Neurosurg. 92, 841–847 (2000).
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang ZG, Zhang RL et al Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32, 2926–2931 (2001).
   PubMed Web of Science ®Google Scholar
• Grotta J for the Combination Therapy Stroke Trial Investigators. Combination therapy stroke trial: recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc. Dis. 12, 258–263 (2001).
   PubMed Web of Science ®Google Scholar
• The US and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment in acute ischemic stroke. Stroke 28, 2338–2346 (1997).
   PubMed Web of Science ®Google Scholar
• Diener HC, Cortens M, Ford G et al Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 31, 2543–2551 (2000).
   PubMed Web of Science ®Google Scholar
• Gibson CM. Time Is Myocardium and Time Is Outcomes. Citrulation 104, 2632–2634 (2001).
   Google Scholar
• Milestones in Acute Myocardial Infarction: Celebrating 10 Years of Insights from the National Registry of Myocardial Infarction. Genentech Inc., South San Francisco, USA 6–7 (2001).
   Google Scholar
• Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial - Italy (MAST-I) Group. Lancet 346, 1509–1514 (1995).
   PubMed Web of Science ®Google Scholar
• Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial - Europe Study Group. N. Engl. Merl 335, 145–150 (1996).
   PubMed Web of Science ®Google Scholar
• Dorman GA, Davis SM, Chambers BR et al Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAIVIA 276, 961–966 (1996).
   PubMed Web of Science ®Google Scholar
• The NINDS t-PA Stroke Study Group. Generalized efficacy oft-PA for acute sbuke. Subgroup analysis of the NINDS t-PA stroke trial. Snake28, 2119–2125 (1997).
   PubMed Web of Science ®Google Scholar
• Tanne D, Gorman MJ, Bates VE et al and the tPA Stroke Survey Group. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older. The tPA Stroke Survey Experience. Stroke 31, 370–375 (2000).
   Google Scholar